Molecular Diagnostics Research Group (MDRG)

About Us

The Molecular Diagnostics Research Group (MDRG) at NUI Galway comprises researchers engaged in the design and development of rapid molecular diagnostics tests for infectious diseases and cancer, using proprietary molecular diagnostic technologies. The MDRG focus is on novel target discovery, and the design, development and commercialisation of new molecular diagnostic approaches for the diagnosis, management and monitoring of infectious diseases, and cancer. The MDRG has over 25 years’ experience in the development and application of molecular diagnostic tests for the detection and identification of microorganisms (bacteria, fungi and yeast species). Recently, we have expanded our activities into cancer biomarker discovery and molecular diagnostics assay development. The MDRG, led by Prof Terry Smith, has published its research widely, and has an substantial patent portfolio, with 16 granted patents and over 50 patent applications, based on proprietary Nucleic Acid Diagnostic detection target technologies. The group collaborates with national and international academic partners, and has worked successfully with a number of Irish and global industry partners to co‐develop and commercialise molecular diagnostic test products based on our proprietary platform target technologies. Through these research collaborations and co‐development partnerships, the MDRG has developed a range of core R&D competencies over the years, including:
  • Infectious Disease Molecular Target Discovery
  • Infectious Disease Test Design, Development & Clinical Evaluation
  • Diagnostic test Co‐Development and Commercialisation
  • Cancer Biomarker Discovery
  • Integration of tests onto “Next generation” Diagnostic Platforms

"Infectious diseases and cancer remain as leading causes of death worldwide. Improved diagnostic tests for the early and accurate detection and identification of microbial pathogens or cancer biomarkers underpin efforts to devise and rapidly implement new therapeutic approaches as well as to monitor disease treatment and recurrence".